NEW YORK (GenomeWeb) – Foundation Medicine and EmergingMed said today that they will partner to offer clinical trial navigation services for health care providers and their patients who have received one of Foundation Medicine's tumor genomic profiling tests.
The firms will provide concierge services to help physicians identify appropriate clinical trials for patients based on the results of FoundationOne or FoundationOne Heme. EmergingMed will provide "Clinical Trial Navigators" to educate and match patients to clinical trials based on their genomic profiles.
"By providing clinical trial navigation services, we aim to facilitate timely and accurate clinical trial information and enrollment support services for physicians and patients, enabling greater access to treatment options based on the unique genomic profile of a patient's cancer," Foundation Medicine Chief Medical Officer Vincent Miller said in a statement.
Currently, there are over 800 candidate therapies that target genomic alterations in clinical trials, but "patients and physicians must identify and act on relevant options when the patient's clinical profile is aligned with the often short enrollment window for each trial," EmergingMed CEO Courtney Hudson said in a statement.
Miller added that these investigational therapies "offer relevant and rational options for patients with cancer, particularly for those whose cancer has progressed or returned following standard treatment."
The new service will also send updates to users when new clinical trials emerge that match a patient's genomic and clinical profile, Hudson said.
The service will be added at no extra cost and will be widely available to patients and their healthcare providers before the end of the year.